Overbeck, Tobias R.

[["dc.bibliographiccitation.firstpage","864"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","871"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Daldrup, Benjamin"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:58:48Z"],["dc.date.available","2018-11-07T08:58:48Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose: To test for an association between high-grade acute organ toxicity during adjuvant radiation and chemotherapy and treatment outcome in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Institutional review board approval was obtained for this retrospective study. From September 1994 to October 2008, 294 HNSCC patients were treated with adjuvant radiation and chemotherapy at the authors' department. They received normofractionated (2 Gy per fraction) irradiation to include associated nodal drainage sites, for a cumulative dose of 60-64 Gy. From January 2002 to December 2009, 91 patients received additional concomitant cisplatin-based chemotherapy. Toxicity during treatment was monitored weekly according to the common toxicity criteria (CTC); any CTC toxicity grade 3 or higher, including mucositis, dysphagia, or skin reaction, was considered high-grade acute organ toxicity. The influence of possible prognostic factors on overall survival and locoregional control was studied by means of uni- and multivariate Cox regression. Results: A statistically significant association was found between high-grade acute organ toxicity and both overall survival and locoregional control. Patients with CTC grade 3 or greater acute organ toxicity had a 5-year overall survival and locoregional control rate of 90% and 97%, respectively, as compared with 24% and 74%, respectively, in patients without such toxicity (P < .01). Multivariate analyses revealed that this association was independent from other factors that may influence treatment toxicity, especially concomitant chemotherapy and/or radiation therapy. Conclusion: The data suggest that normal tissue and tumor tissue may behave similarly with respect to treatment response, as high-grade acute organ toxicity during radiation and chemotherapy was associated with better outcomes in the patient population; therefore, the hypothesis should be further analyzed on the biomolecular and clinical level and with other tumor entities in prospective clinical trials. (C)RSNA, 2011"],["dc.identifier.doi","10.1148/radiol.10100705"],["dc.identifier.isi","000287573100023"],["dc.identifier.pmid","21339350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23729"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.title","High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Adjuvant Radiation and Chemotherapy for Locally Advanced Head and Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","184"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Herrmann, M."],["dc.contributor.author","Kertesz, Tereza"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Christiansen, H."],["dc.date.accessioned","2018-11-07T11:15:52Z"],["dc.date.available","2018-11-07T11:15:52Z"],["dc.date.issued","2008"],["dc.format.extent","134"],["dc.identifier.isi","000255034700367"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54464"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","14th Annual Congress of the Deutschen-Gesellschaft-fur-Radioonkologie/25th Annual Conference of the Osterreichischen-Gesellschaft-fur-Radioonkologie-Radiobiologie-und-Mediz inische-Radiophysik"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","0179-7158"],["dc.title","Effectiveness and toxicity of low dose, daily cisplatine-application (6 mg/m2 body surface) for the combined radiochemotherapy of local advanced head-throat-tumor"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Bosch, Jan"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.date.accessioned","2018-11-07T08:43:05Z"],["dc.date.available","2018-11-07T08:43:05Z"],["dc.date.issued","2010"],["dc.format.extent","127"],["dc.identifier.isi","000278071200346"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19871"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","16th Annual Meeting of the German-Society-of-Radio-Oncology"],["dc.relation.eventlocation","Magdeburg, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Higher grade acute organ toxicity (fflCTC grade 3) during preoperative radio (chemo) therapy as a prognostic factor in patients with local advanced, inoperable squamous cell carcinoma of the head and neck area (oral cavity, oropharynx, larynx, hypopharynx)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","967"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Kertesz, Tereza"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:28:13Z"],["dc.date.available","2018-11-07T08:28:13Z"],["dc.date.issued","2009"],["dc.description.abstract","To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC). From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m(2)/every radiotherapy-day). Acute toxicity a parts per thousand yengrade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received > 80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity a parts per thousand yengrade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients. We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials."],["dc.identifier.doi","10.1007/s00432-008-0532-x"],["dc.identifier.isi","000266477900012"],["dc.identifier.pmid","19107519"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3539"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16373"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-1335"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","262"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","268"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Bosch, Jan"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:43:53Z"],["dc.date.available","2018-11-07T08:43:53Z"],["dc.date.issued","2010"],["dc.description.abstract","To test for a possible correlation between high-grade acute organ toxicity during primary radio(chemo)therapy and treatment outcome in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). From 05/1994 to 01/2009, 216 HNSCC patients were treated with radio(chemo)therapy in primary approach. They received normofractionated (2 Gy/fraction) irradiation including associated nodal drainage sites to a cumulative dose of 70 Gy. 151 patients received additional concomitant chemotherapy (111 patients 5-fluorouracil/mitomycin C, 40 patients cisplatin-based). Toxicity during treatment was monitored weekly according to the Common Toxicity Criteria (CTC), and any toxicity grade CTC a parts per thousand yen 3 of mucositis, dysphagia or skin reaction was assessed as high-grade acute organ toxicity for later analysis. A statistically significant coherency between high-grade acute organ toxicity and overall survival as well as locoregional control was found: patients with CTC a parts per thousand yen 3 acute organ toxicity had a 5-year overall survival rate of 44% compared to 8% in patients without (p < 0.01). Thereby, multivariate analyses revealed that the correlation was independent of other possible prognostic factors or factors that may influence treatment toxicity, especially concomitant chemotherapy and radiotherapy technique or treatment-planning procedure. These data indicate that normal tissue and tumor tissue may behave similarly with respect to treatment response, as high-grade acute organ toxicity during radio(chemo)therapy showed to be an independent prognostic marker in the own patient population. However, the authors are aware of the fact that a multivariate analysis in a retrospective study generally has statistical limitations. Therefore, their hypothesis should be further analyzed on biomolecular and clinical levels and other tumor entities in prospective trials."],["dc.identifier.doi","10.1007/s00066-010-2136-z"],["dc.identifier.isi","000277453900003"],["dc.identifier.pmid","20437012"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20081"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Primary Radio(chemo)therapy for Locally Advanced, Inoperable Head and Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","97"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:47:54Z"],["dc.date.available","2018-11-07T08:47:54Z"],["dc.date.issued","2010"],["dc.description.abstract","Nasopharyngeal carcinomas (NPC) are radiosensitive, and radiotherapy is the standard curative treatment. Furthermore, it has been shown that combined radiochemotherapy improves prognosis in locally advanced stages. Further encouraging results have been obtained with adjuvant interferon-beta after primary radio(chemo)therapy in childhood undifferentiated NPC. Aim of the present study was to evaluate the treatment results after long-term follow-up after radio(chemo)therapy for adult NPC with special reference to patients with undifferentiated carcinomas treated with adjuvant interferon-beta. From 02/1992 to 07/2008, 26 adult patients with NPC without distant metastases were treated (17 squamous cell carcinomas, 9 undifferentiated carcinomas). The treatment concepts changed over the years: 13 patients were treated with radiotherapy alone, 13 patients received combined radiochemotherapy. Additionally, six patients with undifferentiated carcinomas were treated with adjuvant interferon-beta after radiochemotherapy for 6 months. After a median follow-up of 96 months, 17 patients remain alive. Collectively, our 5-year overall-survival and loco-regional control rates were 74% (radiochemotherapy 81%, radiotherapy alone 68.5%) and 87% (radiochemotherapy 100%, radiotherapy alone 72.7%), respectively. All treatment regimens used were feasible; especially, adjuvant interferon-beta was applied as provided without high grade toxicity. All patients with undifferentiated carcinomas treated with adjuvant interferon-beta stayed alive until the end of the follow-up. In summary, our data affirm that NPC in adults are curable by primary radio(chemo)therapy. Furthermore, our data indicate that adjuvant interferon-beta application in undifferentiated NPC in adults is feasible and shows promising results. Further prospective clinical trials are needed to finally establish adjuvant interferon beta in curative treatment of adult NPC."],["dc.identifier.doi","10.1007/s00432-009-0640-2"],["dc.identifier.isi","000271981600011"],["dc.identifier.pmid","19618214"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4152"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21075"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-5216"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Daldrup, Benjamin"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.date.accessioned","2018-11-07T08:43:05Z"],["dc.date.available","2018-11-07T08:43:05Z"],["dc.date.issued","2010"],["dc.format.extent","127"],["dc.identifier.isi","000278071200345"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19872"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","16th Annual Meeting of the German-Society-of-Radio-Oncology"],["dc.relation.eventlocation","Magdeburg, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Higher grade acute organ toxicity (fflCTC grade 3) during adjuvant radio (chemo) therapy as a prognostic factor in patients with local advanced squamous cell carcinoma of the head and neck area (oral cavity, oropharynx, larynx, hypopharynx)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]